Phillip Comalander
Gerontology · Foley, ALNPI 1376086553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 34.2% of the total. 2025 is the largest year on record at $2,266, 3.2 times the $712 reported in 2021. Among gerontology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Phathom Pharmaceuticals, Inc.$557
- Madrigal Pharmaceuticals$539
- Takeda Pharmaceuticals U.S.A., Inc.$466
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$455
- Johnson & Johnson$424
- plus $2K from 22 others
What the payments were for
- Food & beverage$6,40398%
- Education$1612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 143 | $2,243 |
| Phathom Pharmaceuticals, Inc. | 29 | $557 |
| Madrigal Pharmaceuticals | 12 | $539 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $466 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $455 |
| Johnson & Johnson | 19 | $424 |
| Gilead | 14 | $367 |
| Lilly USA, LLC | 10 | $183 |
| Regeneron Healthcare Solutions, Inc. | 7 | $175 |
| Merck | 9 | $167 |
| Braintree Laboratories, Inc. | 7 | $155 |
| Aimmune Therapeutics, Inc. | 2 | $139 |
| Ironwood Pharmaceuticals, Inc | 8 | $137 |
| Ardelyx, Inc. | 5 | $81 |
| QOL Medical, LLC | 2 | $70 |
| Janssen Scientific Affairs, LLC | 1 | $60 |
| Pfizer | 3 | $58 |
| Sanofi | 2 | $58 |
| Redhill Biopharma Inc. | 3 | $46 |
| Intercept Pharmaceuticals, Inc. | 3 | $40 |
| Novo Nordisk | 2 | $28 |
| Alcresta Therapeutics, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
| Amgen | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,564 in reported general payments places this provider in the 90th percentile of 143 gerontology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 26 | $713,098 |
| LinzessLinaclotide | 150 | $131,856 |
| CreonLipase/Protease/Amylase | 27 | $124,662 |
| ZenpepLipase/Protease/Amylase | 27 | $103,996 |
| RinvoqUpadacitinib | 12 | $75,631 |
| XifaxanRifaximin | 20 | $60,203 |
| TrulancePlecanatide | 25 | $23,795 |
| Mesalamine ErMesalamine | 38 | $14,897 |
| MovantikNaloxegol Oxalate | 25 | $14,503 |
| Mesalamine | 39 | $13,805 |
| Dexlansoprazole DrDexlansoprazole | 32 | $10,541 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 169 | $10,381 |
| Colestipol Hcl | 113 | $10,010 |
| Adefovir Dipivoxil | 13 | $9,961 |
| Pantoprazole Sodium | 730 | $8,204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $424 | $713,09826 claims |
| AbbVieLinzess, Creon, Rinvoq | $2,243 | $332,149189 claims |
| Aimmune Therapeutics, Inc.Zenpep | $139 | $103,99627 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $455 | $83,99845 claims |
| Redhill Biopharma Inc.Movantik | $46 | $14,50325 claims |
| Braintree Laboratories, Inc.Suflave | $155 | $3,86231 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $15 | $2,05512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 gerontology providers in Alabama.
Other gerontology in Foley
- Ryan ShannonMontgomery$66K
- Claire BruceHuntsville$12K
- Michelle SanfordMobile$11K
- Virginia McNeillNorthport$11K
- Esther LangeBirmingham$10K
- Sari CapiloutoMontgomery$9K
- Melissa WatkinsDothan$8K
- Melissa HornBirmingham$7K
- Rachel HawesBirmingham$7K
- Stephanie FoutsMobile$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.